

PHA5789C Patient Care VII: Brain and Behavior

Spring 2026 | 6 Credit Hours – [A-E Grading]

Seventh of an eight-course sequence that prepares the student to provide patient-centered care by serving as a collaborative interprofessional team-member who is an authority on pharmacotherapy. The course continues to prepare the student to be a collaborative team member since learning involves teamwork. This course focuses on providing patient-centered care to patients who have disorders involving the brain and behavior. Learners will develop, integrate, and apply knowledge from the foundational disciplines (i.e., pharmaceutical, social/behavioral/administrative, and clinical sciences) and apply the Pharmacists' Patient Care Process in solving case-based scenarios of these patients.

Course Prerequisites: Completion of all Year 2 Pharm.D. program coursework including milestones.

Course Corequisites: PHA5166L Professional Skills Lab VI

Course Faculty and Staff

Course Director	Instructional Designer
John Markowitz, Pharm.D., BCPP Office: MSB P4-31 Phone: 352-273-6262 Email: jmarkowitz@cop.ufl.edu	Chris Egan, M.Ed., NRP, CHSE Email: cegan@ufl.edu
Academic Coordinators	
Ashleigh Langford (GNV) Email: lynn8597@cop.ufl.edu	Jessica Linares (ORL) Email: Jnoriegalinaires@ufl.edu
Jaime Welsh (JAX) Email: jaimewelsh@ufl.edu	Nadja Rivera (ORL) Email: nl.riverarivera@ufl.edu
Teaching Faculty	
Jane Aldrich, Ph.D. Email: jaldrich@cop.ufl.edu	Kalen Manasco, Pharm.D., BCPS, BCPPS, FCCP, FPPA Email: kmanasco@cop.ufl.edu
William (Bill) Allen, JD, MDiv Email: wmallen@ufl.edu	Christopher McCurdy, Ph.D., B.S.Ph, FAAPS Email: cmccurdy@ufl.edu
Lola Bakare, Pharm.D. Email: lbakare@ufl.edu	Philip Melchert, Pharm.D. Email: Melchertphilip@ufl.edu
Erin Bruce, Ph.D. Email: ebruce5@ufl.edu	Carol Motycka, Pharm.D., BCACP Email: motycka@cop.ufl.edu
Kelsey Cook, Pharm.D., BCPS Email: kelsey.cook@ufl.edu	Jason Powell, Pharm.D., BCACP Email: jpowell@cop.ufl.edu
Francine Azeredo, Ph.D., B.Pharm. Email: francinej@ufl.edu	Rachel Reise, Pharm.D., MS, CPh Email: rreise@cop.ufl.edu
Charles Frazier, Ph.D. Email: frazier@cop.ufl.edu	Teresa Roane, Ph.D. Email: troane@cop.ufl.edu
Brian Gawronski, Pharm.D. Email: briangaw@ufl.edu	Bethany Shoulders, Pharm.D., BCPPS Email: bshoulders@cop.ufl.edu
Amie Goodin, Ph.D., MPP Email: amie.goodin@ufl.edu	Dawn Sollee, Pharm.D., DABAT Email: sollee@poison.ufl.edu
Oliver Grundmann, Ph.D. Email: grundmann@ufl.edu	Katherine Vogel Anderson, Pharm.D., BCACP Email: kvanderson@cop.ufl.edu
Marco Bortolato, MD PhD Email: mbortolato@ufl.edu	Brandon Warren, Ph.D. Email: brandon.warren@cop.ufl.edu

Michelle Jacobs-Elliot, M.D. Email: mejacobs@ufl.edu	Chengguo Xing, Ph.D. Email: chengguoxing@cop.ufl.edu
Tracy Leonard, RPh, BCPP, BCACP Email: tracy.leonard@cop.ufl.edu	

[Faculty and Staff: Who to Contact and Questions to Ask](#)

Office Hours: Please see the Canvas course site for posted office hours.

Faculty Locations:

Gainesville	PTR: MSB 0445, PG-22 PEP: HPNP 2336 POP: DSIT 5th floor CSP: MSB P1-20 MC: MSB P3-12 PC: P-320
Jacksonville	Tower 2, First Floor
Orlando	UFRAC 420

Course Objectives and Educational Outcomes

Course Objectives	Linked Educational Outcome
<p>1. Collect: Gather subjective and objective information and analyze the data in order to understand the relevant medical/medication history and clinical status of the patient.</p> <ul style="list-style-type: none"> i. Subjective and objective information is collected through comprehensive medication review with the patient, medical record review, pharmacy profile review, and communication with other members of the health care team. ii. A holistic review is initiated during collection in order to consider physiological, psychological, and sociological variables of the patient and this view is maintained throughout the patient care process. 	Communicator, Problem-solver, Provider
<p>2. Assess: Assess the information collected and formulate a problem list consisting of the patient's active medical problems and medication therapy problems in order to prioritize medication therapy recommendations to achieve the patient's overall health goals.</p> <ul style="list-style-type: none"> i. Assess the patient's active medical conditions taking into account clinical and patient goals of therapy. ii. Assess the indication, effectiveness, safety, adherence, and convenience (administration, access, affordability) of each medication the patient is taking. iii. Include in the assessment an evaluation of risk factors, relevant psychosocial issues, and the need for preventative care or for referral to another healthcare practitioner for further evaluation. iv. Formulate a medication therapy problem list, classifying the patient's medication therapy problems based on indication, effectiveness, safety, and compliance. v. Prioritize the patient's medication therapy problems. 	Problem-solver, Provider
<p>3. Plan: Develop an individualized patient-centered care plan in collaboration with other health care professionals and the patient/caregiver that is evidence-based and</p>	Provider

<p>as affordable as possible.</p> <ul style="list-style-type: none"> iii. For each problem, create patient-centered goal(s) in collaboration with the patient/caregiver and other members of the healthcare team. iv. Develop a care plan to manage the patient's active medical conditions and resolve the identified medication therapy problems. v. Identify monitoring parameters to assess effectiveness, safety, adherence, and quality of life. 	
<p>4. Implement: Implement the care plan in collaboration with other health care professionals and the patient/caregiver.</p> <ul style="list-style-type: none"> i. For each condition and associated recommended strategy to resolving identified MTPs, provide the medication order in its entirety, including full drug name, dose, dosage form, route of administration, dosing interval, duration of therapy. <ul style="list-style-type: none"> a. Discuss the care plan with the patient. b. Educate the patient on their medications (which may include explanations of medication action, the regimen or its proper discontinuation, proper medication use and storage, expected results and when to expect them, possible adverse effects, and when and how to follow-up or seek additional care. ii. Where appropriate, contribute to coordination of care by providing documentation to other providers using an evidence-based method of communication, such as SBAR (Situation, Background, Assessment, Recommendation) or SOAP (Subjective, Objective, Assessment, Plan). 	Communicator, Provider
<p>5. Follow-up with the Patient: Monitor and evaluate the effectiveness of the care plan and modify the plan in collaboration with other health care professionals and the patient/caregiver.</p>	Communicator, Provider

Course Resources and Fees

Course Outline

See Appendix A. Please routinely check your Google campus calendar and the Canvas course site for any messages about changes in the schedule including meeting dates/times, deadlines, and room changes.

Required Textbooks/Readings

Use [UF VPN to access UF Libraries Resources](#) when off-campus. The UF HSC library staff can assist you with questions or issues related to accessing online library materials. For assistance contact your College of Pharmacy librarian or visit the [HSC Library Website](#) at this URL: <http://www.library.health.ufl.edu/>

1. Foye VF, Zito SW, Lemke T, Williams DA. Foye's Principles of Medicinal Chemistry, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA, 8th Edition, 2020. ISBN-13:978-1-4963-8502-4
 - Previously purchased for PHA5782C
 - Not available via HSC Library
2. Krinsky DL, Ferreri SP, Hemstreet B, et al. Handbook of Nonprescription Drugs: An Interactive Approach to Self-care. 19th ed. Washington, D.C.: American Pharmacists Association; 2018.
 - Not available via HSC Library
 - Previously purchased for PHA5781 Patient Care I
3. Brunton, L., Hilal-Dandan R., Knollmann BC., Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill Education, New York, NY, 14th Edition, 2023. ISBN-978-1-264-25807-9 Available for FREE on Access Pharmacy: <https://accesspharmacy.mhmedical.com/book.aspx?bookID=3191>
4. DiPiro JT., Yee GC., Posey LM., Haines ST., Nolin TD., Ellingrod V., Pharmacotherapy: A Pathophysiologic Approach.

McGraw-Hill, New York, NY, 12th Edition, 2023. ISBN 978-1-264-26454-4 Available for FREE on Access Pharmacy:

<https://accesspharmacy.mhmedical.com/book.aspx?bookID=3097>

5. Primary literature readings or other documents will be posted in Canvas.

Suggested Textbooks/Readings

Suggested readings will be posted on Canvas.

Other Required Learning Resources

None

Materials & Supplies Fees

None

Evaluation and Grading

Student Evaluation & Grading

The Canvas© gradebook will be set-up using the percentages below to compute the grade.

Assessment Item	Grade Percentage
Quizzes (8 @ 2% each) *Single lowest score dropped	14%
Capstone Assignment	5%
In Class ALS Assessment (2 @ 2% each)	4%
Facilitated Case Discussions	2%
Exam 1	20%
Exam 2	25%
Exam 3 (Comprehensive)	30%
Total	100%

Grading Scale

Percentage	Letter Grade	Percentage	Letter Grade	Percentage	Letter Grade
92.50-100%	A	79.50-82.49%	B-	66.50-69.49%	D+
89.50-92.49%	A-	76.50-79.49%	C+	62.50-66.49%	D
86.50-89.49%	B+	72.50-76.49%	C	59.50-62.49%	D-
82.50-86.49%	B	69.50-72.49%	C-	< 59.50%	E

Rounding of Grades

Final grades in Canvas will be rounded to the 2nd decimal place. If the decimal is X.495 or higher, Canvas will round the grade to X.50. The above scale depicts this policy and grades are determined accordingly. Grade assignment is made using this policy and NO EXCEPTIONS will be made in situations where a student's grade is "close."

University of Florida Honor Pledge and Academic Dishonesty

UF students are bound by The Honor Pledge which states "We, the members of the University of Florida community, pledge to hold ourselves and our peers to the highest standards of honor and integrity by abiding by the Honor Code. On all work submitted for credit by students at the University of Florida, the following pledge is either required or implied: "On my honor, I have neither given nor received unauthorized aid in doing this assignment."

The Conduct Code specifies a number of behaviors that are in violation of this code and the possible sanctions. Expectations for Artificial Intelligence and when use constitutes academic dishonesty is outlined below.

Tendering information (giving your work to another to be copied, giving someone answers to assessment questions, informing another person in a later section about the questions that appear on an assessment that you have taken, or

giving or selling a paper to another student), is considered academic dishonesty. If you have any questions or concerns, please consult the course's Teaching Partnership Leader/Course Director or Assistant Dean for Curricular Affairs.

See the [UF Conduct Code website](#) for more information. If you have any questions or concerns, please consult with the instructor or TAs in this class.

Assignment Descriptions

Quizzes: Quizzes are administered at the beginning of ALS sessions and are to be completed independently. They are administered in a proctored environment, and course policies apply.

Capstone Assignment: Students will participate in a review of content and complete a restricted formulary exercise at the end of the session to compare and contrast different therapies for inclusion on the formulary list. This assignment is completed with specific resources (see Canvas and proctor instructions) and is not administered in a proctored environment. **Students must not use artificial intelligence for completion of this assignment.**

ALS 10 In-Class Assignment: Students will complete a patient case assignment utilizing drug knowledge. This assignment is to be completed independently with open-book resources. Avoid communication with friends, neighbors, teammates, and refrain from using shared documents. Additionally, do not utilize generative AI for assistance.

ALS 14 In-Class Assignment: Students will work in their teams to answer questions related to marijuana using short answers. Students may use their notes and any other sources available to them, including AI. One question will require documentation from a peer reviewed study and proper citation is expected. This assignment is not administered in a proctored environment.

Facilitated Case Discussions: Students will participate in small group discussions on pharmacotherapy of disease topics.

Exams: Students will complete 3 exams to demonstrate mastery of material. These are administered in a proctored environment, and exam policies apply.

Course-Related Policies

UF Resources and Policies

University of Florida resources and policies can be found at this URL: <https://go.ufl.edu/syllabuspolices>

PharmD Course Policies

The Policies in the following link apply to this course. Review the General [Pharm.D. Course Policies](#) carefully, at this URL: <http://curriculum.pharmacy.ufl.edu/current-students/course-policies/>

Attendance Policy

Attendance is mandatory for active learning sessions such as team-based learning sessions, case discussions, laboratory sessions, and other activities that the instructor designates as required. This course has 18 required sessions (ALS, Facilitated Case Discussions, and Capstone). A student who misses greater than 4 session(s) for this course will receive an incomplete in the course and will retake the course during the next offering, resulting in delayed graduation.

Makeup Assignments

Makeup assignments may be required for excused absences from all Active Learning Sessions. Students will be required to complete the makeup assignment within one week of the missed session.

Late Assignments

Late assignments will not be accepted and will result in a grade of zero.

Educational Technology Use

The following technology below will be used during the course and the student must have the appropriate technology and software.

1. ExamSoft™ Testing Platform
2. Canvas™ Learning Management System

For technical support, navigate to [Educational Technology and IT Support Contact Information](#) at this URL: <http://curriculum.pharmacy.ufl.edu/current-students/technical-help/>

Artificial Intelligence (AI) Use for Assessments

The use of generative AI in assessments is prohibited, unless explicitly allowed by the course instructor. Assessments include any submitted work, graded or ungraded, that will be evaluated. These include, but are not limited to, quizzes, exams, assignments, writing projects, etc. If a student is uncertain about the use of AI technology, it is the student's responsibility to ask the instructor prior to beginning the assignment or assessment.

When authorized by the course director/course instructors, students may use AI technologies in the completion of an assessment if they acknowledge all use by naming the technology, describing how it was employed, and adhering to any other requirement stipulated in the assessment's instructions. Failure to acknowledge the use of AI technology or disregarding instructions related to the use of AI for assessments is considered academic misconduct. Students must disclose the use of AI and AI-assisted technologies by following the instructions below.

Application of AI technology must be done with human oversight and control, and students should carefully review and edit the result, as AI can generate outputs that can be incorrect, incomplete, or biased. **Students assume full responsibility for all content, including errors and omissions, if AI is employed.** Additionally, privacy is a concern with AI-generated content. Most commercially available AI systems are not compliant with [HIPAA](#) or FERPA protections, inputting patient or student information is prohibited by federal law.

Instructions to acknowledge the use of AI:

Statement: During the preparation of this assignment I/we, [INSERT NAME/S], used [INSERT TOOL / SERVICE] in order to [INSERT REASON OR PURPOSE]. After using this tool/service, I/we reviewed and edited the content as needed and take full responsibility for the content of the submission.

Penalties for unauthorized use:

Unauthorized use of AI text generators for assessments is considered evidence of academic dishonesty (see [policy on academic dishonesty](#)).

Guidance on Using AI Tools for Learning

You are welcome to use AI tools to support your learning in this course, including for tasks such as brainstorming, outlining, or summarizing complex topics. However, please be aware that AI-generated content may contain false or misleading information. It is your responsibility to critically evaluate and fact-check any information you use. For all assessments, your responses should be based on the content provided in course materials and lectures.

To protect instructional content and comply with university policies, if you choose to create your own study aids using AI, instructor materials (e.g., PowerPoint slides, lecture transcripts, course handouts) may only be uploaded to university-supported, secure platforms such as the Navigator suite of AI tools (<https://it.ufl.edu/ai/>) or Microsoft Copilot (<https://copilot.microsoft.com/>) using your GatorLink credentials. When using Navigator AI, students should select a model approved for handling sensitive data. Individual instructors may choose not to permit the use of their instructional materials with AI tools. Any course materials that are restricted from AI use will be communicated to students through the course learning management system, Canvas.

Students are prohibited from uploading instructor materials to open or non-university-supported AI tools unless they have received written permission from the course instructor. Students are expected to use AI tools responsibly and must not upload any content that violates copyright laws or terms of use. If you are unsure whether an AI tool is appropriate to use, please consult the instructor.

Disability Resource Center

Students with disabilities who experience learning barriers and would like to request academic accommodations should connect with the Disability Resource Center. See the [Get Started with the DRC webpage](#) on the Disability Resource Center site. It is important for students to share their accommodation letter with their instructor and discuss their

access needs, as early as possible in the semester.

Course Evaluation Process

Students are expected to provide professional and respectful feedback on the quality of instruction in this course by completing course evaluations online. Students can complete evaluations in three ways:

1. The email they receive from GatorEvals,
2. Their Canvas course menu under GatorEvals, or
3. The central portal at <https://my-ufl.bluera.com>

Guidance on how to provide constructive feedback is available at <https://gatorevals.aa.ufl.edu/students/>. Students will be notified when the evaluation period opens. Summaries of course evaluation results are available to students at <https://gatorevals.aa.ufl.edu/public-results/>

Appendix A: Course Outline

Date / Time	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
	1	Module	Module 1: Introduction to Brain Therapeutics		John Markowitz
		Unit	Unit 1.1 Pathophysiology: Brain Neurochemistry		
01/05/26	1.1	Lecture Video	Brain Neurochemistry	44	Brandon Warren
		Unit	Unit 1.2 Blood Brain Barrier		
01/05/26	1.2	Lecture Video	Blood Brain Barrier	23	Erin Bruce
		Unit	Unit 1.3 Pharmacology: Anesthetics		
01/05/26	1.3	Lecture Video	General Anesthesia	29	Brandon Warren
	2	Module	Module 2: Neurodegenerative Disorders		John Markowitz
		Unit	Unit 2.1 The Mental Status Exam		
01/05/26	2.1	Lecture Video	Introduction to the Mental Status Exam and Terminology	15	Michelle Jacobs-Elliott MD
		Unit	Unit 2.2 General Principles of Neuropsychiatric Disorder Management		
01/05/26	2.2	Lecture Video	General Principles of Neuropsychiatric Disorder Management	59	John Markowitz
		Unit	Unit 2.3 Medicinal Chemistry of Neurodegenerative Diseases		
01/06/26	2.3.1	Lecture Video	Medicinal Chemistry of Drugs Used for Alzheimer's Disease	19	Jane V Aldrich
01/06/26	2.3.2	Lecture Video	Medicinal Chemistry of Drugs Used for Parkinson's Disease	23	Jane V Aldrich
01/06/26	2.3.3	Lecture Video	Medicinal Chemistry of Drugs Used for Multiple Sclerosis	15	Jane V Aldrich
		Unit	Unit 2.4 Pharmacology of Drugs Used in Parkinson's & Alzheimer's Disease		
01/06/26	2.4.1	Lecture Video	Pharmacology of Therapeutics for Parkinson's Disease	44	Erin Bruce
01/06/26	2.4.2	Lecture Video	Pharmacology of Therapeutics for Alzheimer's Disease	39	Erin Bruce
		Unit	Unit 2.5 Management of Parkinson's Disease		
01/06/26	2.5	Lecture Video	Management of Parkinson's Disease	78	John Markowitz
		Other	Study Aid Table - Comprehensive List of Agents Used in the Treatment of Parkinson's Disease		John Markowitz
		Unit	Unit 2.6 Management of Alzheimer's Disease		
01/07/26	2.6	Lecture Video	Management of Alzheimer's Disease	65	Tracy Leonard
		Unit	Unit 2.7 Multiple Sclerosis		
01/07/26	2.7.1	Lecture Video	Multiple Sclerosis - Part 1	59	Philip Melchert
01/08/26	2.7.2	Lecture Video	Multiple Sclerosis - Part 2	76	Philip Melchert
01/08/26	2.7.3	Lecture Video	Pharmacology of Therapeutics for Multiple Sclerosis	19	Erin Bruce

Date / Time	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
		Unit	Unit 2.8 Appropriate Self-Care (OTC & Herbals) for Patients with Neurodegenerative Disorders		
01/08/26	2.8	Lecture Video	Appropriate Self-Care for Patients with Neurodegenerative Disorders	23	Oliver Grundmann
		Unit	Unit 2.9 Quality Assessment to Develop Targets for QI		
01/08/26	2.9	Lecture Video	Quality Assessment to Develop Targets for Quality Improvement	27	Rachel Reise
01/09/2026, 1-2:50 pm	1	Active Learning Session	Active Learning Session 1: Parkinson's Disease Case Studies	50	Erin Bruce, Jane V Aldrich, John Markowitz, Oliver Grundmann, Rachel Reise, Tracy Leonard
01/09/2026, 3-4:50 pm	2	Active Learning Session	Active Learning Session 2: Alzheimer's Dementia and Multiple Sclerosis Case Studies	50	Erin Bruce, Jane V Aldrich, John Markowitz, Oliver Grundmann, Rachel Reise, Tracy Leonard
		Quiz (In Class)	Quiz 1		
	3	Module	Module 3: Psychotic Spectrum Disorders		John Markowitz
		Unit	Unit 3.1 Background/Etiology of Psychotic Spectrum Disorders		
01/08/26	3.1	Lecture Video	Psychotic Spectrum Disorders: Background and Etiology	45	John Markowitz
		Unit	Unit 3.2 Pathophysiology of Psychotic Spectrum Disorders		
01/08/26	3.2	Lecture Video	Psychotic Disorders: Pathophysiology	23	Marco Bortolato
		Unit	Unit 3.3 Medicinal Chemistry of Drugs Affecting Dopaminergic, Serotonergic Systems, Antipsychotics		
01/09/26	3.3	Lecture Video	Antipsychotics	54	Chris McCurdy
		Unit	Unit 3.4 Pharmacology of Antipsychotic Medications		
01/12/26	3.4	Lecture Video	Antipsychotic Drugs: Pharmacology of Therapeutic Effects and Side Effects	56	Marco Bortolato
		Unit	Unit 3.5 Management of Psychotic Spectrum Disorders		
01/12/26	3.5	Lecture Video	Management of Psychotic Spectrum Disorders: Focus on Schizophrenia	98	John Markowitz
		Other	Study Aid Table - Potential Pharmacokinetic Drug-Drug Interactions with 2nd Generation Antipsychotic Agents		John Markowitz
		Other	Study Aid Table - Second Generation Antipsychotic Medications		John Markowitz
		Unit	Unit 3.6 Social/Health Disparities - Psychiatric Illness		
01/12/26	3.6	Lecture Video	An Introduction to Mental Health Disparities	18	Tracy Leonard
		Unit	Unit 3.7 Pharmaceutical Dosage Formulations of Psychotropic Drugs		
01/12/26	3.7	Lecture Video	Pharmaceutical Dosage Formulations of Psychotropic Drugs	50	Rodrigo Cristofolletti

Date / Time	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
01/13/2026, 1-2:50 pm	ALS 3	Active Learning Session	Active Learning Session 3: Psychotic Spectrum Disorders Case Studies	50	Chris McCurdy, John Markowitz, Marco Bortolato, Rodrigo Cristofolletti
01/13/2026, 3-4:50 pm	ALS 4	Active Learning Session	Active Learning Session 4: Psychotic Spectrum Disorders Case Studies	50	Chris McCurdy, John Markowitz, Marco Bortolato, Rodrigo Cristofolletti
		Quiz (In Class)	Quiz 2		
01/16/2026, 1-3pm		Exam	Exam 1: Modules 1-3	125	
	4	Module	Module 4: Mood Disorders		John Markowitz
		Unit	Unit 4.1 Background and Etiology of Mood Disorders		
01/20/26	4.1	Lecture Video	Background and Etiology of Mood Disorders	64	John Markowitz
		Unit	Unit 4.2 Medicinal Chemistry of Antidepressants		
01/20/26	4.2.1	Lecture Video	Medicinal Chemistry of Antidepressants and Bipolar Disorder - Part 1	34	Chengguo Xing
01/20/26	4.2.2	Lecture Video	Medicinal Chemistry of Antidepressants and Bipolar Disorder - Part 2	44	Chengguo Xing
		Unit	Unit 4.3 Pharmacology of Antidepressant and Mood Stabilizing Drugs		
01/20/26	4.3.1	Lecture Video	Pharmacology of Antidepressant Agents	43	Marco Bortolato
01/20/26	4.3.2	Lecture Video	Pharmacology of Antimanic Agents	17	Marco Bortolato
		Unit	Unit 4.4 Management of Depressive Disorders		
01/20/26	4.4	Lecture Video	Management of Depressive Disorders	101	John Markowitz
		Other	Study Aid Table - Summary of Antidepressant Effects on CYP450 Enzymes		John Markowitz
		Other	Study Aid Table - Tricyclic Antidepressants and Relative Receptor Affinities		John Markowitz
		Unit	Unit 4.5 Management of Bipolar Disorder		
01/21/26	4.5	Lecture Video	Management of Bipolar Disorder	85	John Markowitz
		Other	Study Aid Table - Laboratory Tests and Monitoring for Bipolar Disorder Treated with Mood Stabilizers		John Markowitz
		Other	Study Aid Table - SGA Antipsychotics FDA-Approved for Manifestations of Bipolar Disorder		John Markowitz
		Unit	Unit 4.6 Behavioral Issues in Psychiatric Patients		
01/21/26	4.6	Lecture Video	Behavioral Challenges to Successful Treatment of Psychiatric Patients	27	Teresa Elaine Roane
		Unit	Unit 4.7 Communication with Patients Who Have Mental Health Problems/Talking About Suicide		
01/22/26	4.7	Lecture Video	Working with Patients in Crisis	48	Philip Daniels

Date / Time	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
		Unit	Unit 4.8 Herbals & Depressive Disorders		
01/22/26	4.8	Lecture Video	Herbals & Depressive Disorders	33	Oliver Grundmann
		Unit	Unit 4.9 Personalized Medicine and Antidepressants		
01/22/26	4.9	Lecture Video	Personalized Medicine and Antidepressants	23	Kelsey Cook
01/23/2026, 10-11:50 am	ALS 5	Active Learning Session	Active Learning Session 5: Mood Disorders- Depression Case Studies	50	Chengguo Xing, John Markowitz, Oliver Grundmann, Teresa Elaine Roane
01/23/2026, 1-2:50 pm	ALS 6	Active Learning Session	Active Learning Session 6: Mood Disorders- Bipolar Disorder Case Studies	50	Chengguo Xing, John Markowitz, Oliver Grundmann
		Quiz (In Class)	Quiz 3		
01/26/2026, 9-10:50 am		Facilitated Case Discussion	Facilitated Case Discussion- via ZOOM	100	Bradley Phillips, John Markowitz, Karen Whalen, Teresa Elaine Roane, Tracy Leonard
	5	Module	Module 5: Anxiety and Sleep-Wake Disorders		John Markowitz
		Unit	Unit 5.1 Background/Etiology of Anxiety & Sleep Wake Disorders		
01/23/26	5.1.1	Lecture Video	Background/Etiology of Anxiety & Sleep-Wake Disorders	53	John Markowitz
		Unit	Unit 5.2 Medicinal Chemistry of Benzodiazepines (Anxiolytics & Sleep), Non-Benzodiazepines		
01/26/26	5.2.1	Lecture Video	Medicinal Chemistry of Anxiety & Sleep-Wake - Part 1	33	Chris McCurdy
01/26/26	5.2.2	Lecture Video	Medicinal Chemistry of Anxiety & Sleep-Wake - Part 2	25	Chris McCurdy
		Unit	Unit 5.3 Pharmacology of Benzodiazepines (anxiolytics & sleep), Non-Benzodiazepines		
01/26/26	5.3.1	Lecture Video	Sedatives and Anxiolytics: Benzodiazepines	21	Brandon Warren
01/26/26	5.3.2	Lecture Video	Non-Benzodiazepine Anxiolytics	8	Brandon Warren
01/26/26	5.3.3	Lecture Video	Other Sedatives	16	Brandon Warren
		Unit	Unit 5.4 Management of Sleep-Wake Disorders		
01/27/26	5.4	Lecture Video	Management of Sleep-Wake Disorders	70	John Markowitz
		Other	Study Aid Table - FDA-Approved Hypnotic Agents -- All Classes		John Markowitz
		Other	Study Aid Table - Medications Available for Treating Manifestations of Narcolepsy		John Markowitz
		Other	Study Aid Table - Therapeutic Options for Restless Legs Syndrome		John Markowitz

Date / Time	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
		Unit	Unit 5.5 Management of Anxiety Disorders I (Generalized Anxiety, Panic, Social Anxiety Disorders)		
01/27/26	5.5	Lecture Video	Management of Anxiety Disorders I	61	John Markowitz
		Other	Study Aid Table - Benzodiazepines with FDA-Approved Indications for Anxiety Disorders		John Markowitz
		Other	Study Aid Table - Antidepressants Agents FDA-Approved for Anxiety Disorders		John Markowitz
		Unit	Unit 5.6 Management of Anxiety Disorders II (PTSD, Obsessive Compulsive)		
01/27/26	5.6	Lecture Video	Management of Anxiety Disorders II	33	John Markowitz
		Unit	Unit 5.7 Case Control Studies & Self-Controlled Designs (sampling, ORs vs RRs, specific biases)		
01/27/26	5.7	Lecture Video	Case Control Studies & Self-Controlled Designs	34	Amie Goodin
		Unit	Unit 5.8 Sleep Anxiolytics		
01/27/26	5.8	Lecture Video	Sleep and Anxiolytics	37	Oliver Grundmann
		Unit	Unit 5.9 Sleep Disorders (OTC)		
01/27/26	5.9	Lecture Video	OTC Treatment of Sleep Disorders	36	Erin Lyn St Onge
01/28/2026, 10-11:50 am	ALS 7	Active Learning Session	Active Learning Session 7: Anxiety Disorder Case Studies	50	Amie Goodin, Brandon Warren, Chris McCurdy, Erin Lyn St Onge, John Markowitz, Oliver Grundmann
01/28/2026, 1-2:50 pm	ALS 8	Active Learning Session	Active Learning Session 8: Sleep- Wake Case Studies	50	Amie Goodin, Brandon Warren, Chris McCurdy, Erin Lyn St Onge, John Markowitz, Oliver Grundmann
		Quiz (In Class)	Quiz 4		
	6	Module	Module 6: Epilepsy		Bethany Shoulders
		Unit	Unit 6.1 Introduction to Epilepsy.		
01/29/26	6.1	Lecture Video	Introduction to Epilepsy through the PPCP	28	Lola Bakare
		Unit	Unit 6.2 Medicinal Chemistry of Drugs Used in Epilepsy		
01/29/26	6.2	Lecture Video	Medicinal Chemistry of Drugs Used in Epilepsy	40	Chris McCurdy
		Unit	Unit 6.3 Pharmacology of Drugs Used in Epilepsy		
01/29/26	6.3.1	Lecture Video	Anti-Epilepsy Drugs: Barbiturates & Benzodiazepines	21	Brandon Warren
01/29/26	6.3.2	Lecture Video	Epilepsy - Part 1	50	Charles Jason Frazier

Date / Time	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
01/30/26	6.3.3	Lecture Video	Epilepsy - Part 2	35	Charles Jason Frazier
		Unit	Unit 6.4 Management of Epilepsy		
01/30/26	6.4	Lecture Video	Management of Epilepsy through PPCP	35	Bethany Shoulders
		Unit	Unit 6.5 Management of Epilepsy in Special Populations		
01/30/26	6.5	Lecture Video	Pediatric Epilepsy	46	Kalen Manasco
02/02/2026, 10-11:50 am	ALS 9	Active Learning Session	Active Learning Session 9: Epilepsy Case Studies	50	Bethany Shoulders, Brandon Warren, Charles Jason Frazier, Chris McCurdy, Lola Bakare
		Quiz (In Class)	Quiz 5		
		Unit	Unit 6.6 Acute Management of Epilepsy		
01/30/26	6.6	Lecture Video	Acute Management of Epilepsy	30	Bethany Shoulders
		Unit	Unit 6.7 Pharmacokinetics-Phenytoin, Phenobarbital, Valproic Acid		
01/30/26	6.7	Lecture Video	Pharmacokinetics of Anticonvulsants	46	Rodrigo Cristofolletti
		Unit	Unit 6.8 Legal & Ethical Issues with Epilepsy Patients		
01/30/26	6.8	Lecture Video	Driving and Persons with Epilepsy (PWE)	14	Bill Allen
		Unit	Unit 6.9 Personalized Medicine for Epilepsy		
01/30/26	6.9	Lecture Video	Precision Medicine for Epilepsy	14	Brian Gawronski
02/02/2026, 1-2:50 pm	ALS 10	Active Learning Session	Active Learning Session 10: Epilepsy Case Studies	50	Bethany Shoulders, Bill Allen, Brian Gawronski, Rodrigo Cristofolletti
		Assignment (Graded)	ALS 10 In Class Assessment		
02/04/2026, 1:30-3:30 pm	4-6	Exam	Exam 2: Modules 4-6	125	
	7	Module	Module 7: Other Neuropsychiatric Disorders		John Markowitz
		Unit	Unit 7.1: Etiology and Pathophysiology of Migraine and ADHD		
02/05/26	7.1.1	Lecture Video	Etiology and Pathophysiology of Migraine	34	Erin Bruce
02/05/26	7.1.2	Lecture Video	Etiology and Pathophysiology of ADHD	16	Marco Bortolato
		Unit	Unit 7.2 Medicinal Chemistry of Drugs Used in Migraine Disorders		
02/05/26	7.2	Lecture	Medicinal Chemistry of Drugs Used in Migraine Disorders	20	Chris McCurdy

Date / Time	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
		Video			
		Unit	Unit 7.3 Management of Migraine		
02/05/26	7.3	Lecture Video	Management of Migraine	59	Katherine L Vogel Anderson
		Unit	Unit 7.4 Medicinal Chemistry of Drugs Used in ADHD		
02/05/26	7.4	Lecture Video	Medicinal Chemistry of Drugs Used in ADHD	14	Chris McCurdy
		Unit	Unit 7.5 Pharmacology of Drugs Used in ADHD		
02/06/26	7.5	Lecture Video	Pharmacology of Drugs Used in ADHD	15	Marco Bortolato
		Unit	Unit 7.6 Management of ADHD		
02/06/26	7.6	Lecture Video	Management of ADHD	68	John Markowitz
		Other	Study Aid Table - Available Methylphenidate Formulations		John Markowitz
		Unit	Unit 7.7 Interprofessional Team Conflicts		
02/06/26	7.7	Lecture Video	Team Conflict	17	Katherine L Vogel Anderson
		Unit	Unit 7.8 Patient Reported Outcomes (PROs) and Cost Effective Analysis (CEA)		
02/06/26	7.8	Lecture Video	Patient Reported Outcomes and Cost Effective Analysis	33	Amie Goodin
02/09/2026, 1-2:50 pm	ALS 11	Active Learning Session	Active Learning Session 11: Other Disorders: ADHD Case Studies	50	Amie Goodin, Chris McCurdy, Erin Bruce, Katherine L Vogel Anderson
02/09/2026, 3-4:50 pm	ALS 12	Active Learning Session	Active Learning Session 12: Other Disorders: Headache Case Studies	50	Amie Goodin, Chris McCurdy, Erin Bruce, John Markowitz, Katherine L Vogel Anderson
		Quiz (In Class)	Quiz 6		
	8	Module	Module 8: Special Populations - Geriatrics		Katherine L Vogel Anderson
		Unit	Unit 8.1 Management of Glaucoma		
02/10/26	8.1	Lecture Video	Glaucoma	62	Jason Powell
		Unit	Unit 8.2 Advanced Topics in Geriatrics		
02/10/26	8.2	Lecture Video	Advanced Topics in Geriatrics	51	Katherine L Vogel Anderson
		Unit	Unit 8.3 Special Populations- Geriatric Dosing		
02/10/26	8.3	Lecture Video	Geriatric Dosing	12	Katherine L Vogel Anderson
		Unit	Unit 8.4 Motivational Interviewing: Addressing the Patient's Issue		
02/10/26	8.4.1	Lecture Video	Introduction to the ComMI Modules	14	Teresa Elaine Roane
02/10/26	8.4.2	Video	Motivational Interviewing: Addressing the Patient's Issue	25	Teresa Elaine

Date / Time	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
		Other	(comMlt Module 6)		Roane
		Unit	Unit 8.5 OTC and Herbal Product Use in the Geriatric Community		
02/11/26	8.5	Lecture Video	OTC and Herbal Product Use in the Geriatric Community	22	Katherine L Vogel Anderson
02/16/2026, 10-11:50 am	ALS 13	Active Learning Session	Active Learning Session 13: Geriatrics Case Studies	50	Jason Powell, Katherine L Vogel Anderson, Teresa Elaine Roane
		Quiz (In Class)	Quiz 7		
	9	Module	Module 9: Substance Use Disorders and Clinical Toxicology		Carol Anne Motycka
		Unit	Unit 9.1 Etiology and Epidemiology of Substance Use Disorders		
02/11/26	9.1	Lecture Video	Etiology and Epidemiology of Substance Use Disorders	39	Carol Anne Motycka
		Unit	Unit 9.2 Pharmacology of Addiction Treatment: Ethanol		
02/11/26	9.2	Lecture Video	Pharmacology of Addiction Treatment: Ethanol	69	Marco Bortolato
		Unit	Unit 9.3 Medicinal Chemistry of Addiction Treatment Including Ethanol		
02/12/26	9.3	Lecture Video	Medicinal Chemistry of Addiction Treatment Including Ethanol	30	Jane V Aldrich
		Unit	Unit 9.4 Management of Substance Use Disorders I		
02/13/26	9.4.1	Lecture Video	Management of Substance Use Disorders I	60	Carol Anne Motycka
02/13/26	9.4.2	Video Other	PRN Discussion	15	Carol Anne Motycka
		Unit	Unit 9.5 Management of Substance Use Disorders II		
02/13/26	9.5	Lecture Video	Management of Substance Use Disorders II	39	Carol Anne Motycka
		Unit	Unit 9.6 Management of Substance Use Disorders III		
02/16/26	9.6.1	Lecture Video	Management of Substance Use Disorders III - Part 1	46	Carol Anne Motycka
02/16/26	9.6.2	Lecture Video	Management of Substance Use Disorders III - Part 2	60	Carol Anne Motycka
		Unit	Unit 9.7 Tobacco Management and Drug Testing		
02/17/26	9.7.1	Lecture Video	Tobacco/Nicotine Management	33	Carol Anne Motycka
02/17/26	9.7.2	Lecture Video	At Home Drug Testing	14	Carol Anne Motycka
		Unit	Unit 9.8 Legal & Ethical Issues - Substance Abuse		
02/17/26	9.8.1	Reading	465.015 Violations and Penalties	5	Bill Allen
02/17/26	9.8.2	Video Other	Youtube: Prescription Drug Abuse: Red Flags for Pharmacists and Pharmacy Technicians	13	Bill Allen
		Unit	Unit 9.9 Clinical Toxicology Emergencies		
02/18/26	9.9.1	Lecture Video	Clinical Toxicology Emergencies: Assessment	34	Dawn Sollee

Date / Time	Mod#	Activity	Activity Title	Contact Time (min)	Responsible
02/18/26	9.9.2	Lecture Video	Clinical Toxicology Emergencies: Treatment	47	Dawn Sollee
02/18/26	9.9.3	Lecture Video	Clinical Toxicology Emergencies: Cases	22	Dawn Sollee
02/20/2026, 8-9:50 am	ALS 14	Active Learning Session	Active Learning Session 14: Substance Abuse Case Studies	50	Carol Anne Motycka, Jane V Aldrich
		Assignment (Graded)	ALS 14 In Class Assessment		
02/20/2026, 10-11:50 am	ALS 15	Active Learning Session	Active Learning Session 15: Substance Abuse Case Studies	50	Bill Allen, Carol Anne Motycka, Dawn Sollee
		Quiz (In Class)	Quiz 8		
02/23/2026, 9-10:50 am		Facilitated Case Discussion	Facilitated Case Discussion- via ZOOM	100	Carol Anne Motycka, Eric Egelund, Robin Moorman Li, Teresa Elaine Roane, Tracy Leonard
02/20/2026, 11:50 am - 12:05 pm		Course Evaluation	Course Evaluation		
02/24/2026, 9-11:30 am		Other	Capstone	150	Bethany Shoulders, Carol Anne Motycka, John Markowitz
		Assignment (Graded)	Capstone Restricted Formulary Exercise		
02/27/2026, 9-11 am		Exam	Final Exam: Modules 1-9 (Comprehensive)		
			Total Contact Hours in Course:	92.88	